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Available online 16 October 2017Background: There is a strong reciprocal relationship between heart failure (HF) and diabetes mellitus (DM).
Shared pathophysiological mechanisms might be a possible explanation. Therefore, we hypothesised that
biomarkers linked to HF would also predict new-onset type 2 DM in the general population.
Methods and results: We utilized the Prevention of Vascular and Renal End-stage Disease (PREVEND) cohort
(mean age 48.9 years, 51% female) to study the relationship between HF and DM in 7953 participants free of
baseline HF and DM. Multiple HF-related, inﬂammation-related and renal function-related biomarkers were
evaluated regarding their predictive utility in new-onset DM. Incidence of DM in participants who developed
HF was 11.8%, versus 5.4% in those who had not developed HF (p b 0.001). Incidence of HF in participants who
developed DM was 8.5%, versus 3.8% in those who had not developed DM (p b 0.001). Classical HF biomarkers,
NT-proBNP and hs-TnT were not associated with an increased risk for new-onset DM. However, inﬂammatory
biomarkers hs-CRP [hazard ratio (HR) 1.16, (95% CI 1.05 to 1.29), p = 0.005], procalcitonin [HR 1.34, (95% CI
1.07 to 1.69), p= 0.012] and PAI-1 [HR 1.55, (95% CI 1.37 to 1.75), p b 0.001] remained signiﬁcantly associated
with new-onset DM, even after multivariable adjustment for established predictors of DM.
Conclusions: Although HF and DM have a strong correlation with each other, systemic biomarkers that predict
HF do not have a predictive value in new-onset DM. This suggests that other, indirect, pathophysiological
mechanisms related to inﬂammation may explain their strong relation.






Heart failure (HF) is a complex clinical syndrome characterized by
impaired circulation and systemic neurohormonal activation. Despite
improvements in therapy and management its global prevalence is
rising, rendering HF a serious health problem with a 5-year mortality
of around 50% and a 10-year mortality of around 75% [1,2].
HF and diabetes mellitus (DM) have several common risk factors
and shared pathophysiological mechanisms, and recent literature
mounts signiﬁcant evidence on the reciprocal relationship between HF
and DM. The incidence of HF in patients with DM is higher than in the
general population; there is approximately a 2.5 fold increased risk of
contracting HF in diabetics than in healthy individuals [3]. HF is also
an insulin resistant state [4,5] and patients with HF develop type 2 DM
(T2DM) more often [6]. Insulin resistance associated with HF can be
localized to the myocardium (myocardial insulin resistance) or itgy, University Medical Center
erlands.could be generalized, affecting multiple organ systems [7]. Insulin
resistance developing in HF might, however, be a reversible state: HF
patients on ventricular assist device (VAD) demonstrated a signiﬁcant
improvement in their glycaemic parameters [8]. Therefore, our study
aimed to examine whether classic HF biomarkers have a predictive
value in new-onset DM, or if other domains (e.g. neuroendocrine
activation, endothelial activation, ﬁbro-inﬂammatory axis and renal
axis) might better reﬂect the complex pathophysiology of HF and DM.
2. Methods
The PREVEND (Prevention of REnal and Vascular ENd-stage Disease) study is a pro-
spective Dutch cohort taken from the general population of Groningen, the Netherlands
between the year 1997 and 1998. An in-depth description of the PREVEND study can be
found elsewhere [9–11].
From the baseline cohort (N = 8592), patients with baseline DM (N = 331) and
participants with no follow-up data or who could not be linked to a pharmacy registry
(N = 289) were excluded. Patients with baseline HF (N = 19) were also excluded,
generating a ﬁnal total of 7953 individuals free of DM and HF with complete follow-up
data for DM. The PREVEND study is in accordance with the principles charted out in the
Helsinki declaration. Approval from the local medical ethical committee was obtained
and informed consent was provided by all participants, including the consent to link
their data with pharmacy-dispensing data.
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Participants attended two outpatient sessions between 1997 and 1998 which consti-
tuted the baseline examination. Study subjects fasted before the visit (water or tea was
allowed) and provided a ﬁrst morning urine sample. Venous blood was drawn into
EDTA tubes; aliquots were made and stored at\\80 °C until analysis. The biomarkers
tested were high-sensitive troponin-T (hs-TnT) [12], N-terminal pro-B-type natriuretic
peptide (NT-proBNP) [13], mid-regional pro-A-type natriuretic peptide (MR-proANP)
[14], C-terminal pro-endothelin-1 (CT-proET-1) [15], renin [9], aldosterone [9],
C-terminal pro-arginine vasopressin (copeptin) [16], mid-regional pro-adrenomedullin
(MR-proADM) [17], high-sensitive C-reactive protein (hs-CRP) [18], procalcitonin [19],
plasminogen activator inhibitor-1 (PAI-1) [20], galectin-3 [21], urinary albumin excretion
(UAE) [22], serum creatinine [17] and cystatin-C [17]. Details of the assays can be found in
the data supplement. The ﬁrst follow up session was done in 4.2 ± 0.4 years, the second
follow-up in 6.5 ± 0.7 years and the ﬁnal follow-up in 9.5 ± 0.8 years after the baseline
examination. The total follow-up period was 11.4 ± 3.2 years.
2.2. Deﬁnitions
Incident T2DMwas deﬁned as a fasting plasma glucose ≥ 7.0 mmol/L (126mg/dL),
random sample plasma glucose ≥ 11.1mmol/L (200mg/dL), self-reporting of a physician di-
agnosis or initiation of glucose-lowering medication use retrieved from central pharmacy
registry [23]. Incident HF was identiﬁed using criteria described in the HF guidelines of the
European Society of Cardiology [10]. Blood pressure was measured using an automatic
Dinamap XL Model 9300 series device and ten blood pressure measurements were taken
during 10 min; systolic and diastolic blood pressures were calculated as the mean of the
last two measurements. Hypertension was deﬁned as systolic blood pressure
N 140 mmHg, diastolic blood pressure N 90 mmHg or self-reported usage of antihyperten-
sivemedication. Body-mass index (kg/m2)was calculated as the ratio ofweight to (height)2.
Waist-hip ratio was calculated as the ratio betweenminimal waist circumference and
hip circumference. Hypercholesterolaemia was deﬁned as total serum cholesterol
≥ 6.5 mmol/L (251 mg/dL) or a serum cholesterol ≥5.0 mmol/L (193mg/dL) if a his-
tory of myocardial infarction (MI) was present or when lipid lowering medication was
used. History of MI or cerebrovascular accident (CVA) was deﬁned as participant-
reported hospitalization for ≥3 days as a result of this condition. Smoking status of the pa-
tient was determined based on self-reports. Smoking was deﬁned as current smoking or
smoking cessation within the previous year. Glomerular ﬁltration rate was estimated
using the simpliﬁed modiﬁcation of diet in renal disease (sMDRD) formula [24]. UAE
was given as the mean of the two consecutive 24-hour urine collections.
2.3. Statistical analysis
All statistical analyses were carried out using STATA, version 14 and a p-value b 0.05
indicates statistical signiﬁcance. As the PREVEND cohort has an overrepresentation of
subjectswith increased UAE, a statistical correction factorwas employed using aweighted
Cox regressionmodel, so that the conclusions may be extended to the general popula-
tion [10,11]. A weighing factor of 11.92 was assigned to people with UAE b 10 mg/L
and a weighing factor of 1.66 to those with UAE N 10mg/mL, based onunequal inclusion
probabilities. Normally distributed data are presented asmean± standard deviation (SD)
and data that are not normally distributed are presented as median ± interquartile
range (IQR). Categorical variables are presented as percentages. Skewed variables were
2-log transformed in order to facilitate interpretation, i.e. in these cases, the risk estimates
should be interpreted as the relative risk if the values of variables were doubled (e.g. from
1 mg/L to 2 mg/L).
Differences between two groups for normally distributed data were tested using two
sample t-test while a Wilcoxon rank-sum test was used for non-normally distributed
data. Differences between categorical variables were tested using Pearson's chi-square
test. To estimate incidences of DM and HF, we used the Nelson-Aalen cumulative risk
estimator. Proportionality assumptions were assessed with Schoenfeld residuals and Cox-
proportional hazards models were ﬁtted to the data; crude hazard ratios (HR) were evalu-
ated to assess the univariate association of individual HF biomarkers with new-onset DM.
Those variables that displayed a statistical signiﬁcance in this univariable model were
further analysed using three models. The ﬁrst model was adjusted for age and sex
and only those variables that reached signiﬁcance (p b 0.1) were included in the second
multivariable model, which was also adjusted for classical risk factors of DM [25]. Those
biomarkers that reached a signiﬁcance of p b 0.05 in the second model were included in
the third model which also corrected for insulin resistance. Models that did not fulﬁl
proportionality assumptions were also assessed with logistic regression to give odds ratio
(OR). Results are summarized as HRs or ORs with 95% conﬁdence intervals (CIs) based on
standard error estimates. Interpretation of the ﬁnal results was done after performing a
Bonferroni type adjustment for multiple analyses, and a p value b 0.0125 (=0.05/4) was
deemed signiﬁcant.
3. Results
3.1. Clinical characteristics at baseline
The study included 7953 participants that were free from both HF
and DM at baseline. Subject characteristics were divided accordingto the incidence of DM [see Table 1]. Individuals who developed
DM were typically older and predominantly male (N = 59%), with a
more frequent history ofMI and CVA compared to those that did not de-
velop DM. Comorbidities such as hypertension, hypercholesterolaemia,
and obesity were more common in those who developed T2DM.
Furthermore, they had higher triglyceride levels and insulin resistance
(HOMA-IR) index, and exhibited impairment of renal function with el-
evated serum creatinine, increased mean 24-hour UAE and reduced
eGFR. Several HF biomarkers were also signiﬁcantly higher in the dia-
betic subgroup but stretch-related markers NT-proBNP and MR-
proANP, and markers of the renin-angiotension-aldosterone axis
showed no signiﬁcant differences between the groups.
3.2. Reciprocal relation between HF and DM
3.2.1. DM incidence
The incidence of new-onset DM was 5.6% during the follow up
period of 11 years (N = 447/7953) as shown in [Fig. 1a]. There was
a 119% increase in the risk of developing DM in participants who
developed HF; total incidence of DM in participants who developed
HF was 11.8% (N = 38/322), versus 5.4% (409/7631) in those who did
not develop HF (p b 0.001) [Fig. 1b].
3.2.2. HF incidence
The 11-year incidence of new-onset HF was 4.0% (N = 321/7953)
[Fig. 1c] and there was a 113% increase in the risk of developing
HF in participants who developed DM. The incidence of HF in
participants who developed DM was 8.5% (N = 38/447), versus 3.8%
(N=283/7506) in those who did not develop DM (p b 0.001) [Fig. 1d].
3.3. Temporal association of HF and DM
Around 0.48% of the participants (N = 38/7953) developed both
DM and HF, and in this subgroup 32% developed DM after HF. The
mean duration of onset of HF was 4.1 ± 2.0 years and that of DM
was 6.5 ± 2.2 years; the average duration of onset of DM after HF
was 2.4 ± 1.8 years. The remaining 68% developed DM before HF;
the mean duration of onset of DM was 5.3 ± 2.0 years, the mean
duration of onset of HF was 9.1 ± 2.3 years and the average duration
of HF onset after DM was 3.8 ± 2.5 years.
3.4. Association of insulin resistance and central obesity with HF
Further analysis revealed that participants who developed HF but
did not develop DM (N = 283) demonstrated a signiﬁcant increase
in insulin resistance [HOMA-IR: 1.92 (1.37–3.09) vs 1.57 (1.07–2.43),
p b 0.001] and also had elevated serum glucose levels at baseline
(5.0 ± 0.7 mmol/L vs 4.7 ± 0.6 mmol/L, p b 0.001) compared to those
who did not develop both HF and DM (N = 7223) [Supplement 2].
Additionally, we observed that participants who developed both DM
and HF had a signiﬁcantly higher waist-hip ratio (central obesity)
compared to those who only developed DM [Supplement 1].
3.5. Relationship of HF biomarkers with new-onset DM
Firstly, we validated the association of “HF biomarkers” with new-
onset HF [26] [Supplement 4]. Then, the relationship between HF
and new-onset DM was evaluated using 15 biomarkers that addressed
various pathophysiological scenarios occurring in HF [Table 2].
The classic HF markers, NT-proBNP and MR-proANP and markers
of neuroendocrine activation, renin and aldosterone displayed no
predictive value in new-onset DM.
Those biomarkers thatwere signiﬁcantly associatedwith new-onset
DM in the crude analyses were further analysed using three models to
characterize a potentially independent association of HF biomarkers
with new-onset DM. PAI-1, hs-CRP, procalcitonin, co-peptin, MR-
Table 1
Baseline characteristics of subjects (N= 7953) according to the status of diabetes mellitus.





N= 7506 N = 447
Age & Sex Age (years) 48.6 ± 12.6 54.8 ± 10.4 b0.001
Sex (female), N (%) 3880 (51.7%) 182 (40.7%) b0.001
Medical history Smoking (last 1 year), N (%) 2869 (38.3%) 164 (36.7%) 0.490
Hypertension, N (%) 1857 (24.7%) 219 (49.0%) b0.001
Hypercholesterolaemia, N (%) 1885 (25.4%) 176 (39.9%) b0.001
Myocardial infarction, N (%) 404 (5.5%) 38 (8.7%) 0.005
CVA, N (%) 67 (0.9%) 11 (2.5%) 0.001
Anthropometry BMI, kg/m2 25.8 ± 4.1 29.4 ± 4.6 b0.001
Waist-hip ratio 0.87 ± 0.09 0.94 ± 0.08 b0.001
Haemodynamic parameters Systolic BP, mm Hg 127.8 ± 19.8 140.1 ± 20.3 b0.001
Diastolic BP, mm Hg 73.6 ± 9.6 78.7 ± 9.5 b0.001
Blood chemistry Cholesterol, mmol/L 5.6 ± 1.1 6.0 ± 1.2 b0.001
LDL, mmol/L 3.7 ± 1.1 4.0 ± 1.0 b0.001
Triglycerides, mmol/L 1.1 (0.8–1.6) 1.7 (1.2–2.5) b0.001
HDL, mmol/L 1.3 ± 0.4 1.1 ± 0.3 b0.001
Glucose, mmol/L 4.7 ± 0.6 5.6 ± 0.8 b0.001
Insulin, mIU/L 7.7 (5.4–11.3) 13.0 (8.8–19.4) b0.001
HOMA-IR 1.58 (1.08–2.45) 3.20 (2.13–5.08) b0.001
Serum creatinine, μmol/L 83.5 ± 15.1 86.3 ± 18.0 b0.001
eGFR, mL/min per 1.73m2 80.8 ± 14.4 78.9 ± 14.6 b0.007
UAE, mg/24 h 9.1 (6.2–16.2) 13.4 (7.8–33.8) b0.001
Cystatin-C, mg/L 0.77 (0.69–0.87) 0.81 (0.72–0.92) b0.001
Heart failure biomarkers hs-TnT, ng/L 2.5 (2.5–4.0) 3.0 (2.5–6.0) b0.001
NT-proBNP, ng/L 38.0 (17.2–73.5) 33.6 (14.6–70.3) 0.130
MR-proANP, pmol/L 47.7 (34.8–64.9) 47.4 (32.5–66.7) 0.720
Co-peptin, pmol/L 4.6 (2.8–7.4) 5.6 (3.5–8.3) b0.001
Renin, mIU/mL 18.0 (11.1–28.3) 18.3 (10.1–29.1) 0.860
Aldosterone, pg/mL 117.9 (92.9–152.1) 118.1 (91.5–153.4) 0.800
MR-proADM, nmol/L 0.37 (0.29–0.45) 0.42 (0.33–0.50) b0.001
CT-proET-1, pmol/L 34.4 (24.4–43.8) 37.2 (25.7–47.5) b0.001
PAI-1, ng/mL 67.6 (39.5–117.7) 124.2 (81.5–189.8) b0.001
hs-CRP, mg/L 1.2 (0.5–2.8) 2.1 (1.1–4.5) b0.001
Procalcitonin, ng/L 1.6 (1.3–1.9) 1.8 (1.5–2.2) b0.001
Galectin-3, ng/mL 10.8 (9.0–13.0) 11.3 (9.8–13.9) b0.001
CVA, cerebrovascular accident; BMI, body-mass index; LDL, low-density lipoprotein;HDL, high-density lipoprotein;HOMA-IR, homeostaticmodel assessment
(estimated insulin resistance); eGFR, estimated glomerular ﬁltration rate; UAE, urinary albumin excretion; hs-TnT, high-sensitive troponin-T; NT-proBNP, N-
terminal pro-B-type natriuretic peptide; MR-proANP, mid-regional pro-A-type natriuretic peptide; MR-proADM, mid-regional pro-adrenomedullin; CT-
proET-1, C-terminal pro-endothelin-1; PAI-1, plasminogen activator inhibitor-1; hs-CRP, high-sensitive C-reactive protein.
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(p value b 0.05) in the ﬁrst model after adjusting for age and sex. These
biomarkers, together with those that had a p value b 0.1 in the ﬁrst
model i.e. hs-TnT and cystatin-C, were analysed using the second
model, whichwas also adjusted for classical risk factors of DM, name-
ly smoking, hypertension, waist-hip ratio and family history of DM.
After multivariable adjustment only hs-CRP, procalcitonin, PAI-1
and copeptin had an independent association with new-onset DM (p
b 0.05). After also adjusting for insulin resistance in the third fully-
adjusted model, only the inﬂammation-related biomarkers hs-CRP
[hazard ratio (HR) 1.16, (95% CI 1.05 to 1.29), p=0.005], procalcitonin
[HR 1.34, (95% CI 1.07 to 1.69), p= 0.012] and PAI-1 [HR 1.55, (95% CI
1.37 to 1.75), p b 0.001] remained independently associated with
new-onset DM. Copeptin displayed a trend towards association [HR
1.18 (1.01–1.38), p = 0.033)]. Logistic regression was performed in
models that demonstrated a signiﬁcant interaction with time and the re-
sults were similar to Cox regression models [Supplement 3].
4. Discussion
Wedemonstrate the reciprocal relationship betweenHF andDM in a
large cohort of the general population,with each disorder increasing the
risk of development of the other. This study aimed to identify common
pathophysiological pathways underlying HF and DM, and to provide a
deeper insight into mechanisms by which HF can cause DM. To this
end, we utilized 15 biomarkers reﬂecting different pathophysiologicalscenarios occurring in HF and evaluated their relationship with new-
onset DM.
Our results indicate that classic HF biomarkers (i.e. NT-proBNP,
MR-proANP and hs-TnT), which signiﬁcantly predict HF development,
did not have any predictive value in the incidence of T2DM. On the
other hand, biomarkers related to inﬂammation, hs-CRP, procalcitonin
and PAI-1 were signiﬁcantly associated with DM, even after multi-
variable correction and displayed a predictive utility in new-onset
DM. Increasing levels of copeptin (surrogate marker of vasopressin)
also increased the risk of new-onset DM; although copeptin reﬂects
neurohormonal activation, it could also be associated with systemic
inﬂammatory responses through indirect mechanisms involving
hypertension and endothelial dysfunction [27,28].
DM is an established risk factor for HF and is involved in cardiac
damage through various macrovascular and microvascular mecha-
nisms, and also via direct cardiotoxic effects of hyperglyceamia and
hyperinsulinaemia [29]. HF is also an independent risk factor for the
development of T2DM (cardiac diabetes), however, underlying patho-
physiological mechanisms are poorly characterized [4,5]. In our study,
we observed that participants who developed HF, but remained free
of DM (N = 283) were also insulin-resistant, and had signiﬁcantly
elevated baseline serumglucose levels compared to those that did not de-
velop HF and DM, indicating that insulin resistance and hyperglycaemia
are closely associated with HF even before the clinical diagnosis of HF
is established, and such individuals should therefore be more intensively
screened for HF.
Fig. 1. (1a) Incidence of new-onset DM in 11 (±3) years starting from the second visit. (1b) Incidence of new-onset DM stratiﬁed by HF starting from the second visit
(1c) Cumulative incidence of new-onset HF in 11 (±3) years starting from the ﬁrst visit (1d) Cumulative incidence of new-onset HF stratiﬁed by DM starting from
the ﬁrst visit. HF, heart failure; DM, diabetes mellitus.
Table 2
Relationship of HF biomarkers with new-onset DM in 7953 subjects free of DM and HF*.
Biomarkers Univariable p value Model 1 p value Model 2 p value Model 3 p value
Adjusted for age, sex Multivariable adjusted ǂ Fully adjusted §
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Myocardial injury & stretch hs-TnT 1.58 (1.42–1.77) b0.001 1.19 (0.99–1.43) 0.064 1.12 (0.92–1.36) 0.261 –
NT-proBNP 0.96 (0.87–1.07) 0.453 – – –
MR-proANP 1.07 (0.85–1.35) 0.545 – – –
Endothelial markers CT-proET-1 1.02 (1.01–1.03) 0.001 1.01 (0.99–1.02) 0.320 – –
Neuroendocrine activation Renin 0.99 (0.85–1.15) 0.877 – – –
Aldosterone 1.10 (0.86–1.40) 0.460 – – –
Co-peptin 1.37 (1.20–1.57) b0.001 1.23 (1.06–1.44) 0.008 1.19 (1.02–1.39) 0.025 1.18 (1.01–1.38) 0.033
MR-proADM 2.22 (1.56–3.16) b0.001 1.49 (1.03–2.15) 0.032 1.28 (0.91–1.81) 0.160 –
Inﬂammation hs-CRP 1.33 (1.24–1.44) b0.001 1.31 (1.20–1.42) b0.001 1.22 (1.11–1.35) b0.001 1.16 (1.05–1.29) 0.005
Procalcitonin 1.78 (1.56–2.03) b0001 1.54 (1.31–1.80) b0.001 1.48 (1.25–1.76) b0.001 1.34 (1.07–1.69) 0.012
PAI-1 1.89 (1.71–2.09) b0.001 1.79 (1.61–2.00) b0.001 1.64 (1.46–1.84) b0.001 1.55 (1.37–1.75) b0.001
Fibrosis Galectin-3 1.52 (1.17–1.97) 0.002 1.18 (0.88–1.58) 0.280 – –
Kidney function UAE 1.30 (1.21–1.39) b0.001 1.19 (1.10–1.30) b0.001 1.08 (0.98–1.18) 0.115 –
Cystatin-C 2.30 (1.62–3.27) b0.001 1.43 (0.99–2.07) 0.055 1.34 (0.98–1.85) 0.070 –
Creatinine 1.02 (1.01–1.02) b0.001 1.00 (0.99–1.01) 0.526 – –
HF – heart failure; DM – diabetes mellitus.
CI, conﬁdence interval; HR, hazard ratio; hs-TnT, high-sensitive troponin-T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; MR-proANP, mid-regional pro-A-type natriuretic peptide;
CT-proET-1, C-terminal pro-endothelin-1;MR-proADM,mid-regional pro-adrenomedullin; hs-CRP, high-sensitive C-reactive protein; PAI-1, plasminogen activator inhibitor-1; UAE, urinary al-
bumin excretion.
* Hazard ratios for CT-proET-1 and creatinine are presented per unit increase. Hazard ratios for other biomarkers are presented per doubling of biomarker.
Biomarkers with p-value b 0.1 in Model 1 were included for further analysis using Model 2
ǂ Adjusted for age, sex, smoking status, hypertension, waist-hip ratio and family history of diabetes mellitus.
Proportional hazards were not satisﬁed in these models, and therefore can be interpreted as an “average effect” over time points that are observed in our dataset.
Biomarkers with a p-value b0.05 in Model 2 were included for analysis in the fully adjusted Model 3.
§ Adjusted for all variables in multivariable model and also for insulin resistance.
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be dangerous. HF leads to systemic hypoxia and to maximize energy
efﬁciency under such conditions, the failing heart shifts its metabolism
from fatty acids to glucose as the major fuel [30]; when superimposed
with the myocardial insulin resistant state, utilization of glucose as an
alternate energy substrate is also hampered resulting in exacerbation
of the pre-existing HF. Therefore, HF patients should also be more
intensively monitored for (myocardial) insulin resistance.
To the best of our knowledge, there are no prospective cohort
studies that describe the temporal associations of DM and HF. This
study reveals that DM can either precede or follow HF, and validates
that HF is an insulin resistant state. It has been demonstrated in other
studies that VAD improved insulin resistance inHFpatients signiﬁcantly
[8], and therefore we speculated that markers ofmyocardial stretch (i.e.
natriuretic peptides)would be associatedwith T2DMashaemodynamic
unloading improved glycaemic parameters. This was not the case and
our results indicate that classic HF biomarkers might not be related to
the pathophysiological mechanisms of new-onset DM. However,
inﬂammation-related biomarkers signiﬁcantly predict new-onset DM,
this strongly suggests that an indirect “inﬂammatory” pathway links
HF biomarkers to new-onset DM [Fig. 2]. It also leads us to hypothesise
that HF could cause T2DM through complex immuno-inﬂammatory
mechanisms.
Systemic inﬂammation is an important risk factor for HF [31,32];
some risk-prediction charts already incorporate hs-CRP in HF risk
estimation [33] and JUPITER study demonstrated that the excess
cardiovascular risk associated with inﬂammation (hsCRP) is amena-
ble to statin therapy [34]. Elevated procalcitonin levels are associat-
ed with a worse prognosis in HF patients, even in those with no
evidence of infection, suggesting that co-existing systemic inﬂam-
mation could be responsible for clinical deterioration of these
patients [35]. Although PAI-1 is a surrogate marker of endothelial
thrombo-inﬂammation [36,37], its role in HF seems to be ambigu-
ous; elevated PAI-1 levels increase the risk of MI in individuals
[38], however, genetic inhibition of PAI-1 in murine models displays
severe cardiac-speciﬁc ﬁbrosis [39].
Inﬂammatory pathways are also indicated in the pathogenesis of
DM, and adipose tissue appears to be a source of various inﬂammatory
proteins. Our study shows that elevated PAI-1 levels were strongly
associated with the incidence of new-onset DM. Individuals who
developed T2DM also demonstrated a signiﬁcant increase in waist-hip
ratio, indicating that PAI-1, DM and central obesity are closely related.
This is also in line with previous studies that demonstrated a signiﬁcantFig. 2. Inﬂammation links insulin resistance in T2DM andHF. Classic HF biomarkers have a
predictive value in new-onset HF but are not associatedwith new-onset DM. On the other
hand, inﬂammation-related biomarkers are signiﬁcantly associated with the risk of
development of both DM and HF, suggesting that complex immuno-inﬂammatory
mechanisms might be responsible for insulin resistance and DM arising against the
backdrop of HF. DM, diabetes mellitus; T2DM, type 2 diabetes mellitus; HF, heart failure.association between PAI-1 levels and the amount of visceral adipose
tissue [40]; overexpression of PAI-1 has also been observed in cultured
adipocytes and in adipose tissue ofmice and humans [41] strengthening
the concept that (visceral) adipose tissue is an important source of
PAI-1. Interestingly, PAI-1 KO mouse models on high-fat diet displayed
a signiﬁcant reduction in obesity, hyperglycaemia and hyperinsulinaemia
compared to wild type mice fed on a similar diet [42]. Thus, it is highly
plausible that visceral adipose tissue affects the glycaemic balance of
the body through PAI-1, and that PAI-1 could be a therapeutic target in
DM and obesity.
Procalcitonin, usually mentioned in the context of infection, could
also be elevated in obesity-associated low-grade inﬂammation. Several
studies have demonstrated that procalcitonin is associatedwith chronic
low-grade inﬂammation, obesity and insulin resistance in the general
population [19,25]. In in-vitro experiments, adipocytes stimulated by
macrophages secrete procalcitonin, and hypoperfused adipose tissue is
widely considered as a non-neuroendocrine depot of procalcitonin
[43,44].
CRP is a widely used marker of inﬂammation, and is secreted by
hepatocytes as an acute-phase response to systemic inﬂammatory
triggers. However, recent evidence also indicates alternative sources of
CRP in chronic low-grade inﬂammation, e.g. adipose tissue, suggesting
that CRP could have a greater role in obesity-related pathophysiologies,
including metabolic syndrome [45].
Taken together with the results from our study, common risk factors
involving systemic immuno-inﬂammatory activation appear to play a
crucial role in the etiology of both HF and DM, and visceral adipose
tissue correlates strongly with the incidence of both these disorders.
Other mechanismsmight also operate in HF that increase the risk of
new-onset DM. Certain HF medications e.g. β-blockers and thiazide
diuretics are known to increase the risk of DM in patients with hyper-
tension [46]. However, data from the NAVIGATOR trial revealed that in
patients with impaired glucose tolerance, diuretics were associated
with an increased risk of DM while β-blockers and calcium channel
blockerswere not [47].We should also acknowledge that, paradoxically,
certain anti-inﬂammatory medications, e.g. statins, used in HF could
contribute to the excess risk associated with new-onset DM [47,48].
Nevertheless, this evidence has to be weighed together with the cardio-
vascular protection offered by these drugs, especially in patients with
ischaemia, dyslipidaemia and vascular comorbidities. Finally, NSAIDs
are commonly used anti-inﬂammatory drugs, and appear to lower
glucose levels in T2DM [49]. However, they are known to increase
cardiovascular risk and also HF-related hospitalizations (depending on
the dosage and type of NSAID) [50], raising concerns about their usage
in patients with HF.
This study indicates that inﬂammation plays a key role in HF associ-
ated insulin resistance and T2DM, althoughmechanisms involved in the
immuno-inﬂammatory axis appear to be complex and indirect. Existing
anti-inﬂammatory therapies also give contrasting results in reducing
the risk of new-onset DM. Further studies are needed to elucidate the
inﬂammatory mechanisms operating in DM and HF and how anti-
inﬂammatory therapies could affect their incidence rates. Our study
also underscores the necessity of developing speciﬁc cardioprotective
anti-inﬂammatory therapies that can also reduce the incidence of
new-onset DM.
5. Clinical perspective
DM and HF frequently coexist and this portends an unfavourable
prognosis and increases mortality. Our study reinforces that HF is an
independent risk factor for the development of DM. As the prevalence
of CHF is increasing, the number of patients developing dysglycaemia
and T2DM as a consequence of HF is expected to surge in the coming
years. Effective management (anti-inﬂammatory) strategies to combat
concurrent HF and DM need to be urgently developed to address
this issue.
193N. Suthahar et al. / International Journal of Cardiology 250 (2018) 188–1946. Study strengths and limitations
Firstly, our study is a large community based cohort with a long
follow-up time of 11 ± 3 years. Secondly, temporal associations be-
tween HF and DM could be characterized due to its longitudinal design.
Finally, biomarkers reﬂecting a wide spectrum of cardiovascular patho-
physiological mechanisms were utilized to evaluate their association
with new-onset DM as both these diseases have several shared patho-
physiological mechanisms.
We also acknowledge several limitations of our study. PREVEND
cohort was enriched for increased UAE and is not an exact representa-
tion of the general population; we overcame this over-representation
using a statistical correction method. The subjects included were pre-
dominantly Caucasian, therefore, extension of the results to other
races might not be accurate. Detection bias should also be considered;
patients who developed HF are usually screened more intensely
and therefore, DM arising after HF could have been detected early.
On the other hand, several patients who developed DM might not
have reported to the hospital immediately, and the disease could have
been undiagnosed for a long time. Long-term storage effects in the
samples such as degradation and denaturation must also be taken into
account. Furthermore, our study is purely observational and further
experimental studies are warranted to identify the source(s) and func-
tions of pro-inﬂammatory bio-markers, namely PAI-1, procalcitonin
and hs-CRP.
7. Conclusion
HF is an insulin resistant state and can either follow or precede DM.
Although there is a strong reciprocal relationship between HF and DM,
classic biomarkers that predict new-onset HF do not have a predictive
value in new-onset DM. However, markers of inﬂammation are closely
associated with T2DM. The pathophysiological mechanisms by which
HF causes DM is not direct; complex, indirect pathophysiological
mechanisms involving inﬂammation are indicated. Future studies are
needed to explore the inﬂammatory link between HF and DM.
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